[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"menopause\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:menopause":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,104,0,25,[9,55,88,119,147,171,199,221,250,277,300,323,346,373,395,424,451,474,499,540,562,589,613,636,667],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100650561","haelan-951-for-menopause-symptoms-in-peri--and-postmenopausal-women-100650561",false,"NCT07751029","Haelan 951 for Menopause Symptoms in Peri- and Postmenopausal Women","A Decentralized, Site-Anchored Hybrid, Open-Label, Single-Arm Proof-of-Concept Study Evaluating the Effect of Haelan 951 - a Fermented Soy Conventional Food Product - on Self-Reported Menopausal Vasomotor and Sleep-Related Outcomes in Post- and Peri-Menopausal Women","H951-MENO","Inclusion Criteria:\n\n1. Female sex assigned at birth, ages 45-65 years inclusive at the time of consent.\n2. Post-menopausal (≥12 consecutive months amenorrhea, STRAW+10 stage +1) OR peri-menopausal (STRAW+10 stages -2 or -1) at consent. PI to confirm staging at Screening.\n3. Self-reported vasomotor symptoms ≥3 months' duration prior to Screening, averaging ≥4 episodes per 24-hour period over the 7 days prior to Screening.\n4. Willing and able to consume the investigational product as directed (30 mL twice daily, empty stomach, 30 days).\n5. Willing and able to complete daily eCOA entries in the study application and to wear the study wearable throughout the Treatment period.\n6. Possession of (or willingness to use) a personal smartphone running iOS 16+ or Android 12+, with reliable daily internet access.\n7. Resident of the Kansas City metropolitan area \\[30- 45 mile radius\\] and able to travel to Spectrum Clinical Research for a single onsite Participant Onboarding Visit.\n8. Able to read, understand, and provide written informed consent in English at approximately an 8th-grade reading level.\n9. Willing to abstain from initiation of any new HRT, menopause-related supplement, or other menopause-related therapeutic intervention for the study duration.\n\nExclusion Criteria:\n\n1. Pre-menopausal status (STRAW+10 stage -3 or earlier).\n2. Current pregnancy, planning pregnancy during the study, or breastfeeding.\n3. Current use of any systemic or topical HRT. Required wash-out prior to Day 1: 30 days systemic and 30 days topical\u002Flocal, aligned with the Screening period and the 30-day study duration; the PI may extend for an individual on documented clinical rationale per ICH E6(R3) 4.2.1.\n4. Current use of any menopause-related dietary supplement within 30 days prior to Day 1, unless on a stable regimen ≥3 months and willing to maintain it unchanged (documented in medical history).\n5. Known soy allergy or hypersensitivity to any component of Haelan 951 (Purified Water, Organic Cultured Soy Powder, Yeast, Salt).\n6. History of estrogen- or progesterone-receptor-positive breast cancer; active malignancy of any type; or current systemic chemotherapy, immunotherapy, or radiation therapy.\n7. Heavy alcohol use (≥3 alcoholic beverages\u002Fday on average, per NIAAA definitions).\n8. Major surgical procedure or hospitalization within 90 days prior to Screening, or any unresolved condition that the PI judges would compromise safety or interpretation of endpoints.\n9. Documented uncontrolled or unstable medical condition (e.g., uncontrolled cardiovascular disease; CKD stage 3b or worse; moderate-to-severe hepatic impairment; active autoimmune disease on systemic immunosuppression), established from medical history and PI clinical assessment.\n10. Current use of medications with documented potential for clinically significant interaction with soy-derived foods (thyroid replacement unless dose-stable ≥6 weeks with 4-hour separation; oral anticoagulants on non-stable dose; MAOIs; tamoxifen or other hormone-modulating cancer therapies).\n11. Current or recent (within 30 days) participation in another interventional clinical study.\n12. Inability to provide informed consent (cognitive impairment, language barrier - materials are English-only - or other reason per PI judgment).\n13. Other reasons judged by the PI, with documented rationale per ICH E6(R3) 4.2.1, to compromise safety, well-being, or scientific validity.","FEMALE","45 Years","65 Years",{"count":7,"type":22},"ESTIMATED","INTERVENTIONAL",[25],"NA","This proof-of-concept, open-label, single-arm study is designed to evaluate the effects of daily consumption of Haelan 951, a fermented soy conventional food product, on self-reported menopausal vasomotor symptoms, sleep quality, and health-related quality of life in peri- and postmenopausal women. The study will collect descriptive data on participant-reported outcomes over the study period to assess the feasibility and potential effects of Haelan 951 in supporting menopausal wellness. The study is not intended to evaluate the treatment, prevention, or cure of any disease.",[28,29,30],"Menopause","Menopause Hot Flashes","Menopause Related Conditions",[28,32,33,34,35,36,37,38,39,40,41],"Perimenopause","Vasomotor Symptoms","Hot Flashes","Sleep Quality","Quality of Life","Haelan 951","Fermented Soy","Conventional Food","Decentralized Clinical Trial","Wearable Technology","NOT_YET_RECRUITING","2026-08-06",{"date":45,"type":46},"2026-08-10","ACTUAL",{"date":48,"type":22},"2026-08",{"date":50,"type":22},"2026-10",{"name":52,"class":53},"Spectrum Clinical Research, LLC","NETWORK",1,{"id":56,"slug":57,"hasResults":12,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":18,"minAge":19,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100623239","a-prospective-multicenter-cohort-study-of-contemporary-menopausal-hormone-therapy-and-cardiovascular-outcomes-100623239","NCT07394049","A Prospective Multicenter Cohort Study of Contemporary Menopausal Hormone Therapy and Cardiovascular Outcomes","Cardiovascular Assesment Under Current Hormone Replacement Therapy in Menopause (CATCH-Menopause)","CATCH-Menopaus","Inclusion Criteria:\n\n* female sex\n* Age 45-75 years at enrollment\n* Perimenopausal or postmenopausal status documented according to prespecified clinical criteria\n* Increased cardiovascular risk, defined as SCORE \\> 5 % (age 45-69 years) or SCORE2-OP \\> 5 % (age \\> 70 years), or established disease\n* Established cardiovascular disease includes coronary artery disease, cerebrovascular disease and\u002For peripheral artery disease, as specified in the approved protocol\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C45 years or \\> 75 years\n* Active malignancy at screening\n* Inability to provide written informed consent or to comply with study procedures\n* Severe renal impairment, defined as estimated glomerular filtrate rate \\\u003C30 ml\u002Fmin\u002F1.73m2, or dialysis dependance\n* Advanced liver disease, defined as Child-Pugh class C\n* Known genetic cardiomyopathiy",true,"75 Years",{"count":66,"type":22},3408,"OBSERVATIONAL","This prospective registry study investigates the impact of new hormone replacement therapy (HRT) delivery methods, such as creams, gels, and sprays, on cardiovascular risk in postmenopausal women. Menopause-related estrogen deficiency leads to metabolic and vascular changes that increase atherosclerosis and cardiovascular events. This study hypothesizes that new HRT forms may reduce cardiovascular risk in high-risk women.\"",[70,71,72,28],"Hormone Replacement Therapy","Cardiovascular Diseases","Hormone Replacement Therapy, Post-Menopausal",[74,75,76],"hormone replacement therapy","cardiovascular disease","menopause","2026-07-30",{"date":79,"type":46},"2026-07-31",{"date":81,"type":22},"2026-08-01",{"date":83,"type":22},"2041-03",{"name":85,"class":86},"Heinrich-Heine University, Duesseldorf","OTHER",2,{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":63,"sex":18,"minAge":95,"maxAge":20,"enrollmentInfo":96,"targetDuration":4,"studyType":23,"phases":98,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":54},"100647115","effect-of-whole-or-skimmed-milk-greek-yogurt-on-integrated-muscle-protein-synthesis-glucose-homeostasis-and-cognition-in-post-menopausal-women-100647115","NCT07705724","Effect Of Whole or Skimmed Milk Greek Yogurt on Integrated Muscle Protein Synthesis, Glucose Homeostasis, and Cognition in Post-Menopausal Women","Effect Of Whole or Skimmed Milk Greek Yogurt on Integrated Muscle Protein Synthesis, Glucose Homeostasis, And Cognition in Post-Menopausal Women","Inclusion Criteria:\n\n1. Aged 50 to 65 years\n2. Body mass index ≥25 to \\\u003C40 kg\u002Fm2 or body fat ≥36%\n3. Able to provide informed consent\n4. Absence of menstruation for ≥12 months without the use of hormonal contraceptives, or one of the following:\n\n   * Another medical cause of menopause e.g., history of bilateral oophorectomy\n   * Clinician-confirmed menopausal status for those with hysterectomy and retained\u002Funknown ovaries\n   * Partial\u002Ftotal hysterectomy ≥12 months ago and current age ≥55 years\n\nExclusion Criteria:\n\n1. Allergy or intolerance to dairy products (other allergies or intolerances may be excluded if they are not compatible with the study meals and how they are prepared)\n2. Conditions, medications, or recent changes in medications that cause participants to be metabolically unstable (e.g., renal, cardiovascular, thyroid, polycystic ovary syndrome, type-1 and type-2 diabetes)\n3. Gastric bypass\u002Fbariatric surgery in the previous 5 years\n4. Pregnancy or nursing in the prior 12 months\n5. Weight loss or gain \\>5 kg in the last two months\n6. Unable or unwilling to suspend use of blood thinning medications and non-steroidal anti-inflammatory drugs for the duration of the study\n7. Unwilling to abstain from vigorous exercise for the study period\n8. Does not or will not eat all foods on the standardized diet (e.g., allergies, intolerances, or taste preferences)\n9. Participants may be excluded at the Principal Investigator's discretion if their health or body composition is not compatible with the required study procedures","50 Years",{"count":97,"type":22},40,[25],"The study will examine the impact of adding two servings per day of skimmed or whole milk Greek yogurt on integrated muscle protein synthesis (iMPS), blood sugar control, and cognition in post-menopausal women with overweight and obesity.",[101,102,28],"Obesity & Overweight","Women",[104,105,106,107,108,102,109,110],"Muscle Protein Synthesis","Protein Turnover","Glycemic Control","Cognition","Post-Menopause","Protein","Dairy","2026-07-29",{"date":77,"type":46},{"date":114,"type":22},"2026-10-01",{"date":116,"type":22},"2029-04-01",{"name":118,"class":86},"University of Arkansas",{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":63,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":135,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":142,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100649686","relaxation-training-via-tele-rehabilitation-in-postmenopausal-women-100649686","NCT07737691","Relaxation Training Via Tele-Rehabilitation in Postmenopausal Women","Effects of Tele-Rehabilitation-Based Relaxation Training on Menopausal Symptoms, Sleep Quality, and Fatigue in Postmenopausal Women: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Women in the early postmenopausal period (within 8 years after menopause) Natural or hormonally confirmed menopause with at least 12 consecutive months of amenorrhea Resident of Tekirdağ Province Able to use a smartphone and internet connection Willing to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Presence of a serious cardiac condition, including angina, hypertrophic cardiomyopathy, clinically significant arrhythmia, or a cardiac pacemaker Presence of an advanced orthopedic, neurological, or psychiatric disorder Current use of hormone replacement therapy History of trauma or a medical condition that may prevent participation in the relaxation exercise program Inability to cooperate with or adhere to the study procedures and intervention program",{"count":127,"type":22},30,[25],"Menopause is associated with various physiological and psychological changes that may adversely affect women's quality of life. Menopausal symptoms, sleep disturbances, and fatigue are among the most common complaints during the postmenopausal period. Non-pharmacological interventions, such as relaxation training, have been suggested as effective approaches for managing these symptoms. This randomized controlled trial aims to investigate the effectiveness of a physiotherapist-supervised relaxation training program delivered synchronously via tele-rehabilitation on menopausal symptoms, sleep quality, and fatigue in postmenopausal women. Thirty women in the early postmenopausal period will be randomly assigned to either an intervention group receiving a 6-week tele-rehabilitation-based relaxation training program (twice weekly) or a control group receiving no structured intervention. Outcomes, including menopausal symptoms, sleep quality, objectively monitored sleep parameters, and fatigue, will be assessed before and after the intervention using validated outcome measures. The findings of this study are expected to provide evidence regarding the feasibility and effectiveness of tele-rehabilitation-based relaxation training as a non-pharmacological approach for managing postmenopausal symptoms.",[131,132,133,28,134],"Postmenopausal Symptoms","Telerehabilitation","Relaxation Training","Menopausal Syndrome",[136,132,137,138,139],"Postmenopause","Relaxation training","Menopausal symptoms","Fatigue","2026-07-27",{"date":77,"type":46},{"date":81,"type":22},{"date":144,"type":22},"2026-11-01",{"name":146,"class":86},"Marmara University",{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":63,"sex":18,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":54},"100644665","early-phase-1-beta3-adrenergic-receptors-and-cardiovascular-function-in-aging-women-100644665","NCT07674680","Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women","Inclusion Criteria:\n\n* Healthy women,\n* Assigned female at birth,\n* 18-70 years of age,\n* Body mass index \\\u003C18 or ≥30 kg\u002Fm2,\n\nExclusion Criteria:\n\n* Assigned male at birth,\n* Pregnancy,\n* Breastfeeding,\n* History of hormone replacement therapy, chemical menopause, or oophor-ectomy\n* Polycystic ovarian syndrome or Primary ovarian insufficiency,\n* Current smoking\u002FNicotine use,\n* Blood pressure ≥140\u002F90 mmHg,\n* Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy,\n* Nerve\u002Fneurologic disease,\n* Cardiovascular, hepatic, renal, respiratory disease,\n* Hypersensitivity to nitroglycerin,\n* Diabetes,\n* Communication barriers,","18 Years","70 Years",{"count":156,"type":22},60,[158],"EARLY_PHASE1","To determine if vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.",[102,161,28],"Aging","2026-07-24",{"date":164,"type":46},"2026-07-28",{"date":166,"type":22},"2026-07",{"date":168,"type":22},"2029-05",{"name":170,"class":86},"University of Missouri-Columbia",{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":4},"100649486","phase-4-hormone-therapy-effects-on-brain-heart-health-during-the-menopausal-transition-100649486","NCT07732452","Hormone thERapy Effects on BRAin-HEART Health During the Menopausal Transition","HER BRAVE HEART Trial - Hormone thERapy Effects on BRAin-HEART Health During the Menopausal Transition: A Randomized Feasibility Study","HERBRAVEHEART","Inclusion Criteria:\n\n* Women aged ≥ 45 years.\n* Perimenopausal or postmenopausal, defined as at least one of the following:\n\n  * Perimenopause, defined as menstrual cycle irregularity (changes in cycle length, skipped cycles, or amenorrhea ≥ 60 days) accompanied by vasomotor symptoms consistent with the menopausal transition.\n  * Postmenopause, defined as at least one of:\n\n    * ≥ 12 months of spontaneous amenorrhea, or\n    * bilateral oophorectomy, or\n    * hysterectomy with FSH \\> 40 IU\u002FL when menstrual history is unavailable.\n* Vasomotor symptoms with a negative impact on quality of life, defined as :\n\n  * Recurrent hot flashes (sudden sensations of heat, typically involving the face, neck, or chest, often associated with flushing and\u002For sweating), and\u002For\n  * Night sweats (episodes of excessive sweating during sleep), With associated interference in daily functioning, sleep, or overall quality of life, such that the participant would be an appropriate candidate for systemic menopausal hormone therapy in clinical practice.\n* Presence of at least one cardiovascular risk factor, defined as either:\n\n  * Hypertension (diagnosed hypertension, use of antihypertensive medication, or blood pressure ≥ 140\u002F90 mmHg on screening).\n  * Dyslipidemia (diagnosed dyslipidemia, use of lipid-lowering therapy, LDL ≥ 3.0 mmol\u002FL, or total cholesterol ≥ 5.2 mmol\u002FL).\n  * Type 2 diabetes mellitus, defined as HbA1c ≥ 6.5%, fasting plasma glucose ≥ 7.0 mmol\u002FL, or use of glucose-lowering medication.\n  * Obesity (body mass index ≥ 30 kg\u002Fm²).\n  * Current smoking.\n  * First-degree family history of premature cardiovascular disease, defined as myocardial infarction, stroke, or documented coronary artery disease occurring before age 55 years in a male relative or before age 65 years in a female relative.\n* Eligible for systemic MHT (i.e., no formal contraindication to MHT).\n* Able and willing to undergo research CMR and attend the 12-month follow-up assessment.\n* Able to provide written informed consent.\n* Not currently using systemic MHT at baseline, or willing to discontinue systemic MHT prior to randomization and remain off systemic MHT until allocation and baseline assessments are complete.\n\nExclusion Criteria:\n\n* Prior cardiovascular event or established cardiovascular disease, including myocardial infarction, stroke or TIA, coronary artery disease, heart failure, cardiomyopathy, or clinically significant valvular heart disease.\n* Uncontrolled hypertension or other unstable cardiovascular condition (e.g., unstable angina, decompensated heart failure, uncontrolled arrhythmia).\n* Formal contraindication to systemic menopausal hormone therapy, including estrogen-dependent cancer, unexplained vaginal bleeding, active severe liver disease, severe thrombophilia, antiphospholipid syndrome, prior or active VTE.\n* Standard contraindications to MRI (e.g., MRI-incompatible pacemakers or intracardiac devices, certain metallic implants, metallic foreign bodies in the eye, or severe claustrophobia not manageable).\n* Pregnant.\n* Active cancer on ongoing cardiotoxic chemotherapy.\n* Current use of systemic hormonal therapy outside the study strategy, including systemic menopausal hormone therapy, combined hormonal contraception, or systemic progestin-only contraception, with unwillingness or inability to discontinue prior to baseline and randomization.\n* Ten years or more since menopause, defined as ≥10 years from the final menstrual period or from bilateral oophorectomy\n* Participants currently using combined hormonal contraception or systemic progestin-only contraception who are willing to discontinue must complete a washout period of at least 4 weeks prior to the baseline visit and randomization",{"count":180,"type":22},100,[182],"PHASE4","The goal of this clinical trial is to learn whether it is feasible to conduct a larger study comparing transdermal menopausal hormone therapy (MHT) versus no hormone therapy in menopausal women with vasomotor symptoms (hot flashes and night sweats) and at least one cardiovascular risk factor. The main questions it aims to answer are:\n\n* What proportion of eligible women agree to be randomly assigned to either receive MHT or not?\n* How many participants complete the 12-month follow-up, including repeat heart imaging?\n* Does transdermal MHT affect early changes in heart muscle tissue as measured by cardiac MRI?\n\nResearchers will compare immediate initiation of transdermal estradiol (a skin gel or patch) to a no-hormone therapy strategy to see if MHT influences early cardiovascular and brain-vascular changes over 12 months.\n\nParticipants will:\n\n* Be randomly assigned to start transdermal MHT within 2 weeks, or to use no hormone therapy for at least the first 3 months\n* Undergo a cardiac MRI and retinal eye imaging at the start of the study and again at 12 months\n* Complete cognitive testing and questionnaires about symptoms, sleep, and stress at both visits\n* Provide a blood sample for storage and future analysis of heart and brain health markers\n* Receive follow-up phone calls at 3, 6, and 9 months to review symptoms, medications, and any health changes",[28,32,33,185,186,187,188,189,190],"Cardiovascular Disease Risk Factor","Menopausal Hormone Therapy","Cardiac Remodeling","Myocardial Fibrosis","Microvascular Dysfunction","Cognitive Function Assessment","2026-07-23",{"date":111,"type":46},{"date":194,"type":22},"2026-11",{"date":196,"type":22},"2029-01",{"name":198,"class":86},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":18,"minAge":207,"maxAge":20,"enrollmentInfo":208,"targetDuration":4,"studyType":23,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":4},"100647879","midlife-empowerment-and-longevity-through-optimizing-wellness-100647879","NCT07713862","Midlife Empowerment and Longevity Through Optimizing Wellness","Enhancing Healthy Longevity in At-Risk Midlife Women With Abdominal Obesity: A Digital Phenotyping Commitment Device on Improving Visceral Body Fat Mass, Menopausal Symptoms and Cardiometabolic Risk Factors","MELOW","Inclusion Criteria:\n\n* Women aged 21-65 years old;\n* Report at least mild climacteric symptoms as indicated by an MRS score ≥5;\n* Waist circumference ≥80 cm, indicating abdominal adiposity;\n* Own and use a smartphone compatible with the CGM and Oura Ring.\n\nExclusion Criteria:\n\n* Are currently receiving hormone replacement therapy (HRT);\n* Are currently using oral contraceptives;\n* Have been diagnosed with severe psychiatric illness requiring inpatient care;\n* Are concurrently enrolled in another behavioural or psychotherapy trial;\n* Have significant cognitive impairment or inability to engage with digital tools;\n* Have uncontrolled chronic medical conditions that may interfere with study participation;\n* Unable to comprehend written and spoken English.","21 Years",{"count":209,"type":22},200,[25],"The goal of this observational longitudinal study is to understand how lifestyle behaviours, menopausal symptoms, and digital health data change over time in women experiencing perimenopause or menopause, and to evaluate whether a personalised digital health programme can support healthier lifestyle behaviours and improve cardiometabolic health.\n\nThe main questions it aims to answer are:\n\n1. Can personalised lifestyle recommendations informed by wearable devices, dietary logging, and self-reported symptoms improve adherence to healthy diet, physical activity, and sleep behaviours?\n2. How are menopausal symptoms associated with changes in cardiometabolic health, body composition, physical function, and quality of life over time?\n\nParticipants will:\n\n1. Attend study visits at the National University of Singapore for health assessments, including measurements of body composition, physical function, and cardiometabolic health.\n2. Wear a smartwatch or wearable device to monitor physiological and activity data throughout the study.\n3. Use a mobile application to record dietary intake, menopausal symptoms, and other health-related information.\n4. Receive personalised lifestyle recommendations based on their health data and engage in regular follow-up assessments over the study period.",[28],"2026-07-22",{"date":191,"type":46},{"date":216,"type":22},"2027-01",{"date":218,"type":22},"2030-01",{"name":220,"class":86},"National University Health System, Singapore",{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":63,"sex":18,"minAge":19,"maxAge":154,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":230,"briefSummary":232,"conditions":233,"keywords":236,"overallStatus":242,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":246,"leadSponsor":248,"locationsCount":54},"100621045","phase-1-blackcurrants-modify-gut-microbiota-and-reduce-osteoporosis-risk-in-postmenopausal-females-100621045","NCT07365514","Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females","Blackcurrants Mitigate Postmenopausal Bone Loss Through Gut Microbiota-Bone Axis: A Randomized Clinical Trial Coupled With a Multi-Omics Approach to Inform Precision Nutrition","Inclusion Criteria:\n\n* postmenopausal (defined as no more than 10 years since final menstrual cycle) females aged 45-70 years\n* not on hormone replacement therapy for at least one year before initiation of the study\n* maintaining normal exercise level (\\\u003C 7 hours\u002Fweek) and willing to avoid exercise for 24 hours prior to blood and stool sampling\n* willing to ingest a dietary blackcurrant supplement or placebo (up to 1,176 mg\u002Fday, three 392mg capsules)\n* willing to avoid other dietary supplements for the duration of the study\n* willing to avoid intake of foods extremely rich in anthocyanins and fermented dairy products containing viable Bifidobacteria or Lactobacilli\n* willing to have three blood draws, three stool collections, and three bone scans\n\nExclusion Criteria:\n\n* history of cardiovascular disease, osteoporosis, metabolic bone disease, cancer, diabetes mellitus, arthritis, or other chronic inflammatory diseases\n* current smokers\n* taking prescription medications known to alter bone and calcium metabolism\n* taking anabolic agents such as parathyroid hormone or growth hormone, or steroid within 3 months before the start of the study\n* taking medications that alter bleeding (such as antiplatelets or anticoagulants) or those with a bleeding disorder\n* alcohol consumption exceeding 2 drinks\u002Fday (approximately 14g of ethanol per drink) or a total of 12\u002Fweek\n* those with planned surgery during the study period or within 2 weeks of ending the intervention\n* those with sensitivities or allergies to any of the ingredients for the placebo (rice powder)\n* planning a procedure that includes iodine, barium or nuclear medicine isotopes within the study period\n* UConn students and\u002For employees who any key personnel teach or who report to any key personnel\n* study key personnel, partners of key personnel, or dependents\u002Frelatives of any key personnel",{"count":229,"type":22},159,[231],"PHASE1","The goal of this clinical trial is to evaluate the effects of blackcurrant (BC) supplementation on changes in bone density and gut microbiome composition in postmenopausal females.",[234,235,28],"Postmenopausal Osteoporosis","Gut Microbiome",[237,238,239,76,240,241],"blackcurrant","gut microbiome","osteoporosis","females","bone aging","RECRUITING","2026-07-21",{"date":191,"type":46},{"date":166,"type":22},{"date":247,"type":22},"2029-09",{"name":249,"class":86},"University of Connecticut",{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":63,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":260,"conditions":261,"keywords":269,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":4},"100623836","fascial-yoga-in-menopausal-women-100623836","NCT07401810","Fascial Yoga in Menopausal Women","The Effect of Fascial Yoga on Perceived Stress, Cognitive Control, and Cognitive Flexibility in Menopausal Women","FascialYogaM","Inclusion Criteria:\n\n* Female participants aged 45-65 years\n* In the menopausal period, defined as at least 12 months since the last menstrual period\n* Able to read and understand Turkish and to complete self-report questionnaires\n\nExclusion Criteria:\n\n* Current or past diagnosis of a psychiatric disorder or ongoing psychiatric treatment\n* Regular use of antidepressant, anxiolytic, or corticosteroid medications\n* History of cancer or currently receiving active oncological treatment\n* Participation in fascial yoga, yoga, or similar yoga-based programs within the past 6 months\n* Any medical condition that may prevent safe participation in mild physical activity",{"count":156,"type":22},[25],"Aim:\n\nThe aim of this study is to evaluate the effects of a structured fascial yoga-based behavioral intervention on perceived stress, cognitive control, and cognitive flexibility in menopausal women. The study aims to determine whether a non-pharmacological and non-invasive behavioral intervention can support psychological and cognitive functioning and reduce perceived stress in menopausal women.\n\nDesign:\n\nThis study is designed as a randomized controlled, pretest-posttest experimental study with a post-intervention follow-up assessment. Eligible participants will be randomly assigned to either the intervention group or the control group receiving usual care. Outcomes will be assessed at baseline, immediately after the intervention, and at follow-up to evaluate both the immediate and sustained effects of the intervention.\n\nMethod:\n\nA total of 60 menopausal women aged 45-65 years will be recruited from the menopause outpatient clinic and randomly assigned to either the intervention group or the control group. The intervention group will participate in a 12-week online fascial yoga program consisting of two 60-minute sessions per week.\n\nIn this study, fascial yoga is defined as a fascia-focused, non-pharmacological, and non-invasive behavioral intervention that includes myofascial release techniques, breath regulation, body awareness, and basic yoga practices to support stress regulation and cognitive functioning. The program will include myofascial release techniques, basic yoga postures suitable for all physical fitness levels, and structured breathing exercises. All sessions will be conducted online in a group format, and no audio or video recordings will be taken.\n\nThe control group will continue to receive routine outpatient care during the study period. After completion of the follow-up assessments, the fascial yoga program will be offered to participants in the control group upon request.\n\nData will be collected at three time points: at baseline before the intervention, immediately after completion of the 12-week intervention, and at the follow-up assessment 8 weeks after the intervention. Perceived stress, cognitive control, and cognitive flexibility will be assessed using validated self-report questionnaires.\n\nHypotheses:\n\nH1: Menopausal women participating in the fascial yoga intervention will show a significant reduction in perceived stress levels compared with the control group at post-intervention and follow-up assessments.\n\nH2: Menopausal women participating in the fascial yoga intervention will show a significant improvement in cognitive control and cognitive flexibility compared with the control group at post-intervention and follow-up assessments.",[28,262,263,264,265,266,267,268],"Stress, Psychological","Cognitive Flexibility","Nonpharmacological Interventions","Randomized Controlled Trial","Cognitive Control","Perceived Stress","Yoga",[28,267,263,266,268],"2026-07-20",{"date":213,"type":46},{"date":273,"type":22},"2026-07-01",{"date":275,"type":22},"2027-06-01",{"name":146,"class":86},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":63,"sex":18,"minAge":19,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":23,"phases":285,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":242,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":299},"100591029","phase-2-focusing-on-the-menopausal-transition-to-improve-mid-life-womens-health-100591029","NCT06975111","Focusing on the Menopausal Transition to Improve Mid-Life Women's Health","Inclusion Criteria:\n\n* aged 45-55\n* In the late menopausal transition, defined as 60 days of amenorrhea but less than 365 days of amenorrhea18\n* No current use of hormone therapy or hormonal contraception\n* Presence of a uterus and at least one ovary in order to track menstrual patterns\n* Have a smartphone and broadband access adequate to accept telehealth appointments\n\nExclusion Criteria:\n\n* Lack of broadband access (activity and survey data will be collected electronically whenever possible and some visits will be via telehealth)\n* Lack of regular menstrual periods in mid-reproductive life (ages 25-38) when not on hormones or not pregnant.\n* Pregnancy or actively trying to get pregnant\n* Inability to adhere to study protocol schedule\n* Untreated alcoholism\n* Un- Diagnosed abnormal uterine bleeding\n* Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (MEN 2) for participants with a BMI\\> 30 kg\u002Fm2.","55 Years",{"count":209,"type":22},[286,287],"PHASE2","PHASE3","What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.",[28,29,30,290],"Cardiovascular","2026-07-17",{"date":243,"type":46},{"date":294,"type":46},"2026-03-01",{"date":296,"type":22},"2030-10-01",{"name":298,"class":86},"University of Colorado, Denver",3,{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":63,"sex":18,"minAge":19,"maxAge":64,"enrollmentInfo":307,"targetDuration":4,"studyType":23,"phases":308,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":242,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":54},"100553023","exercise-training-intensity-and-nitrate-supplementation-in-post-menopausal-females-100553023","NCT06480695","Exercise Training Intensity and Nitrate Supplementation in Post-Menopausal Females","Effects of Exercise Training Intensity and Inorganic Nitrate Supplementation on Vascular Health and Fitness in Post-Menopausal Females","Inclusion Criteria:\n\n* Post-menopausal female (greater than age 45 but less than age 75)\n* Sedentary (does not exercise regularly or less than 2 bouts of exercise per week)\n* No major changes in medication in the last 3 months\n\nExclusion Criteria:\n\n* Smokers within last 5 years\n* Weight unstable (loss\u002Fgain of more than 3kg in the past 3 months)\n* Any medical condition that prevents the subject from exercising safely\n* Hormone replacement therapy (current or within last 3 months)\n* Diabetes\n* Currently or recently on vasoactive medications (i.e., calcium channel blockers, statins, ACE or renin inhibitors, ARBs, nitrates, alpha- or beta-blockers, diuretics, proton pump inhibitors, etc.)\n* Oral antibiotic use within previous four weeks\n* Oral disease or poor oral health as determined by the Oral Health Questionnaire\n* Using an antibacterial mouthwash or a mouthwash containing chlorhexidine and unwilling to discontinue use",{"count":97,"type":22},[25],"Menopause greatly increases cardiovascular disease risk (CVD). Current exercise guidelines are inadequate to ameliorate this risk and higher intensity exercise may be necessary for cardiovascular benefits in postmenopausal females. Oral nitrate supplementation enhances exercise performance and CVD risk profile in several clinical conditions. The investigators recently reported that 3-days of nitrate supplementation in postmenopausal females enhances acute post-exercise vascular function, in an intensity dependent manner. The effects of nitrate supplementation and exercise training over a longer training program remains unexplored. This investigation will examine the impact of exercise training intensity with and without inorganic nitrate supplementation, on CVD and fitness outcomes. Postmenopausal females will be tested for maximal oxygen uptake and lactate threshold before randomization to one of four groups: that inorganic nitrate-rich beetroot juice, or beetroot juice with nitrate extracted; and assigned to one-month of calorie matched high-intensity or moderate-intensity exercise training. Vascular function and fitness will be evaluated before and after training.",[28],[312,28,313,314],"Inorganic Nitrate","High Intensity Exercise","Vascular Health","2026-07-15",{"date":291,"type":46},{"date":318,"type":46},"2025-07-01",{"date":320,"type":22},"2026-12-31",{"name":322,"class":86},"University of Virginia",{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":18,"minAge":329,"maxAge":20,"enrollmentInfo":330,"targetDuration":4,"studyType":23,"phases":331,"briefSummary":332,"conditions":333,"keywords":338,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":342,"leadSponsor":344,"locationsCount":4},"100647819","waning-moon-a-whole-person-health-intervention-designed-by-and-for-urban-menopausal-american-indianalaska-native-women-100647819","NCT07713095","Waning Moon: A Whole Person Health Intervention Designed by and for Urban Menopausal American Indian\u002FAlaska Native Women","Inclusion Criteria:\n\nSelf-identifies as American Indian or Alaska Native Female, age 35-65 Experiencing menopause-related symptoms (e.g., vasomotor symptoms) Able to attend sessions at UICSL in Salt Lake City, Utah English-speaking\n\nExclusion Criteria:\n\nCurrently enrolled in another menopause intervention study Do not identify as American Indian or Alaska Native Are not experiencing menopause","35 Years",{"count":127,"type":22},[25],"This study tests the feasibility and acceptability of Waning Moon, a culturally tailored menopause health intervention developed in partnership with the Urban Indian Center of Salt Lake (UICSL) for American Indian\u002FAlaska Native (AI\u002FAN) women. Waning Moon is a 4-session integrative medical group visit program delivered by community health workers and prescribing providers. It covers menopause education, complementary health approaches, and community support. Thirty midlife AI\u002FAN women will participate. The study will assess whether the program is feasible to deliver and acceptable to participants and clinical partners.",[28,334,335,336,337],"Vasomotor Symptoms (VMS)","Women's Health","Health Disparities","American Indian or Alaska Native",[28,33,335,337,336],"2026-07-14",{"date":270,"type":46},{"date":81,"type":22},{"date":343,"type":22},"2028-06-30",{"name":345,"class":86},"University of Utah",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":18,"minAge":353,"maxAge":20,"enrollmentInfo":354,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":356,"conditions":357,"keywords":359,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":54},"100646426","pelvic-floor-symptoms-across-menopausel-stages-100646426","NCT07690137","Pelvic Floor Symptoms Across Menopausel Stages","Comparison of Lower Urinary Tract Symptoms, Bowel Function, and Sexual Health Across Menopausal Stages in Women","Inclusion Criteria:\n\n* Female\n* Age 40-65 years\n* Intact uterus and at least one ovary\n* Perimenopause or postmenopause according to STRAW+10 criteria\n* Able to read and understand Turkish\n\nExclusion Criteria:\n\n* Hormone replacement therapy within the previous 6 months\n* Oral contraceptive use\n* Antipsychotic medication use\n* Previous pelvic surgery\n* Neurological or systemic diseases affecting bladder or bowel function\n* Active urinary tract or vaginal infection\n* Pelvic radiotherapy or chemotherapy history\n* Active gynecological or urological malignancy\n* Alcohol or substance abuse during the previous year","40 Years",{"count":355,"type":22},180,"The menopausal transition is associated with substantial hormonal alterations that may adversely affect lower urinary tract function, bowel function, and sexual health. Although these symptoms are common, few studies have comprehensively evaluated all three pelvic floor compartments across different menopausal stages.\n\nThe aim of this study is to compare lower urinary tract symptoms, bowel symptoms, and female sexual function among women in the perimenopausal, early postmenopausal, and late postmenopausal stages. In addition, the relationship between menopausal stage and symptom severity will be investigated.",[28,358],"Perimenopausal Disorder",[360,361,362,363],"Menopausal transition","Lower urinary tract symptoms","Bowel functions","Sexual functions","2026-07-07",{"date":366,"type":46},"2026-07-09",{"date":368,"type":22},"2026-07-06",{"date":370,"type":22},"2026-10-06",{"name":372,"class":86},"Bezmialem Vakif University",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":63,"sex":18,"minAge":19,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":23,"phases":381,"briefSummary":382,"conditions":383,"keywords":385,"overallStatus":242,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":389,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":393,"locationsCount":54},"100573206","time-efficient-inspiratory-muscle-strength-training-for-reducing-sympathetic-activity-and-improving-sleep-in-midlife-women-100573206","NCT06743269","Time-Efficient Inspiratory Muscle Strength Training for Reducing Sympathetic Activity and Improving Sleep in Midlife Women","Inclusion Criteria:\n\n* Females aged 45-60 with hot flashes.\n* Participants will be recruited from Rochester, MN and surrounding areas.\n* Non-smokers.\n* BMI \\\u003C 40kg\u002Fm\\^2.\n* No history of cardiovascular disease, except for hypertension.\n\nExclusion Criteria:\n\n* Detailed medical and social histories will be collected. To allow for ecological validity, participants will not be excluded for use of menopausal hormone therapy or medications affecting cardiovascular function so long as they have been on a consistent regimen for ≥3 months and during the study period. This approach to medications is consistent with recent work in this area.\n* Participants will be screened for contraindications to inspiratory muscle strength training including, a history of spontaneous pneumothorax, collapsed lung that has not healed fully, a perforated eardrum that has not healed fully, and\u002For any other condition of the eardrum.\n* Additional exclusion criteria will include the use of sleep aids (i.e., prescription, melatonin, doxylamine, valerian root, etc.).","60 Years",{"count":127,"type":22},[25],"The purpose of this research is to understand how training the muscles used for breathing (inhalation) affects menopausal hot flashes, sympathetic nerve activity and sleep.",[28,34,384],"Blood Pressure Regulation",[76,386,387,388],"blood pressure","inspiratory training","hot flashes",{"date":366,"type":46},{"date":391,"type":46},"2025-03-27",{"date":216,"type":22},{"name":394,"class":86},"Mayo Clinic",{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":63,"sex":18,"minAge":353,"maxAge":379,"enrollmentInfo":403,"targetDuration":405,"studyType":67,"phases":4,"briefSummary":406,"conditions":407,"keywords":411,"overallStatus":242,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":423},"100646115","caramel-observational-study-100646115","NCT07695376","CARAMEL Observational Study","CArdiovascular Risk Assessment Via Multimodal Data Analysis Enabling Personalised Prevention Strategies Targeting MEnopausaL Women - Observational Study","CARAMEL-OS","Inclusion Criteria:\n\n* Women 40 to 60 years of age, at recruitment.\n* Ability to understand and complete the required informed consent for the study.\n* Women who are covered by the corresponding healthcare system operating at each clinical site.\n\nExclusion Criteria:\n\n* Severe comorbidity with less than 24 months life expectancy.\n* Lack of basic digital skills to use or carry a smartphone and wearable devices.",{"count":404,"type":22},3000,"24 Months","CARAMEL is a project funded by the European Commission under the Horizon Europe programme. Its aim is to develop a personalized prevention approach based on state-of-the-art artificial intelligence models for cardiovascular risk stratification in women aged 40-60 years. These models are trained using large amounts of multi-source data and complemented by digital self-assessment and self-management tools. The CARAMEL consortium brings together a diverse group of 25 organizations, including technology companies and research centers, clinical institutions, as well as experts in ethics, law, and communication.\n\nThe CARAMEL-OS study is an observational study aimed at prospectively completing the proposed personalized cardiovascular risk stratification model for women aged 40-60 years that will be developed during the earlier phases of the overall CARAMEL project (https:\u002F\u002Fwww.caramel-project.eu\u002F).\n\nThe study has a purely observational design, and patient stratification will not entail any clinical intervention. The data collected will be used to complete the design of the personalized stratification model, as well as to develop and validate the performance of the predictive models in an independent prospective cohort, distinct from the retrospective cohort initially used. The performance of the models developed using retrospective data will be assessed in terms of accuracy, discrimination, calibration, and other relevant metrics. In addition, the study will enable the development of new predictive models with short-term prediction horizons, incorporating additional variables that are not available retrospectively.\n\nThe study population will be recruited in four European Union countries: Croatia, Spain (Andalusia and The Basque Country - Gipuzkoa), Greece and Lithuania; and in Colombia. A prospective cohort of 3,000 women aged 40-60 will be recruited, with each partner contributing 500 participants.",[32,28,408,409,185,410],"Cardiovascular (CV) Risk","Women (Between 30 to 60 Years Old)","Artificial Intelligence (Al)",[412,408,32,28,413,414],"Women-specific risk factors","Prediction models","Patient reported outcomes (PROM)",{"date":416,"type":46},"2026-07-10",{"date":418,"type":46},"2026-03-16",{"date":420,"type":22},"2028-11",{"name":422,"class":86},"Biogipuzkoa Health Research Institute",6,{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":63,"sex":18,"minAge":19,"maxAge":283,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":433,"briefSummary":434,"conditions":435,"keywords":439,"overallStatus":242,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":54},"100356129","phase-2-autologous-prp-intra-ovarian-infusion-to-restore-ovarian-function-in-menopausal-women-100356129","NCT03916978","Autologous PRP Intra Ovarian Infusion to Restore Ovarian Function in Menopausal Women","Investigating Reactivation of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in Menopausal Women","PRP","Inclusion Criteria:\n\n* Age between 45-55 years old\n* Amenorrhea for at least 12 months\n* Discontinuation of any complementary\u002Fadjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment.\n* Willing to comply with study requirements\n\nExclusion Criteria:\n\n* Any pathological disorder related to reproductive system anatomy\n* Previous POI diagnosis\n* Abnormal karyotype\n* Endometriosis\n* Adenomyosis\n* Fibroids and adhesions\n* Infections in reproductive system\n* Current or previous diagnosis of reproductive system cancer\n* History of familiar cancer in reproductive system\n* Severe male factor infertility\n* Prior referral for PGT\n* Ovarian inaccessibility\n* Endocrinological disorders (Hypothalamus-Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome)\n* BMI\\>30 kg\u002Fm2 or BMI\\\u003C18.5 kg\u002Fm2\n* Systematic autoimmune disorders",{"count":180,"type":22},[286,287],"Autologous PRP intra ovarian infusion may restore ovarian function, may promote folliculogenesis and may improve hormonal profile of women in menopause.",[436,437,28,438],"Infertility, Female","Anovulatory Infertility","Amenorrhea",[440,441],"Ovarian rejuvenation","Ovarian reactivation; ovulation","2026-07-05",{"date":444,"type":46},"2026-07-08",{"date":446,"type":46},"2019-05-21",{"date":448,"type":22},"2028-07-30",{"name":450,"class":86},"Genesis Athens Clinic",{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":18,"minAge":458,"maxAge":459,"enrollmentInfo":460,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":4},"100630385","endocrine-disruption-menopause-and-poor-sleep-in-women-with-type-2-diabetes-effects-on-cardiovascular-health-100630385","NCT07486986","Endocrine Disruption, Menopause, and Poor Sleep in wOmen With Type 2 Diabetes: Effects on Cardiovascular Health","EMPOWER","Inclusion Criteria:\n\n* Female Sex\n* Age range 48-58 years\n* In menopausal transition phase (pre-menopause or peri-menopause)\n* Diagnosis of Type 2 Diabetes Mellitus\n* Have access to and regularly use a smartphone with internet access\n\nExclusion Criteria:\n\n* Male Sex\n* Currently Pregnant\n* Prior history of total hysterectomy or bilateral oophorectomy\n* Prior diagnosis of any of the following:\n\nCoronary Vascular Disease (CVD) including coronary heart disease, heart failure, congenital heart disease stroke\u002Ftransient ischemic attack, valvular heart disease, peripheral vascular disease, aortapathy, atrial fibrillation or flutter, other CVD.\n\n\\- Untreated serious mental illness (e.g, untreated psychosis).","48 Years","58 Years",{"count":461,"type":22},381,"EMPOWER aims to determine the overall effect of menopause and sleep disruption on cardiac remodeling in women with type 2 diabetes.",[28,464,465],"Sleep Disruption","T2DM","2026-06-30",{"date":273,"type":46},{"date":469,"type":22},"2026-09",{"date":471,"type":22},"2032-12",{"name":473,"class":86},"Ottawa Heart Institute Research Corporation",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":63,"sex":18,"minAge":353,"maxAge":379,"enrollmentInfo":482,"targetDuration":4,"studyType":23,"phases":484,"briefSummary":485,"conditions":486,"keywords":487,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":4},"100644536","cuidar-me-a-web-based-psychological-intervention-for-perimenopausal-women-a-pilot-randomized-controlled-trial-100644536","NCT07672002","Cuidar-ME, a Web-based Psychological Intervention for (Peri)Menopausal Women: A Pilot Randomized Controlled Trial","A Pilot Randomized Controlled Trial to Evaluate the Acceptability, Feasibility and Preliminary Efficacy of a Web-based Psychological Intervention to Promote Well-being and Mental Health During (Peri)Menopause","Cuidar-ME","Inclusion Criteria:\n\n* Being female;\n* Being between 40 and 60 years old;\n* Being in perimenopause or natural post-menopause;\n* Residence in Portugal;\n* Having access to a computer, tablet, or smartphone and internet (a necessary - condition to complete the program);\n* Being able to read and write in Portuguese.\n\nExclusion Criteria:\n\n* Having menopause induced by medical or surgical reasons;\n* Presence of a severe physical medical condition (self-reported);\n* Presence of a severe psychiatric illness (self-reported);\n* Presence of suicidal ideation.",{"count":483,"type":22},150,[25],"The Cuidar-ME program is a web-based cognitive-behavioral intervention designed to promote well-being and mental health in women during (peri)menopause. The main goal of this research is to evaluate its acceptability, feasibility and preliminary evidence of efficacy of the intervention. This pilot randomized controlled trial uses a two-arm design and serves as a preliminary step before a full-scale RCT.\n\nA sample of at least 150 (peri)menopausal women, aged 40 to 60, will be recruited online. Participants who meet the eligibility criteria will be randomly assigned to either the web-based intervention (Cuidar-ME) or a waitlist control condition (which will receive access to the program after the study concludes).\n\nParticipation in this study will last approximately 3 months. Participants in both conditions will be invited by the researchers via email to complete baseline and post-intervention assessments. These assessments will include self-report questionnaires evaluating several outcomes (e.g., quality of life, menopausal symptoms, depressive and anxiety symptoms, menopause representations, etc.), potential mechanisms of treatment response (emotional regulation and self-compassion), as well as user acceptability and feasibility.",[28,32],[28,488,489,36,490],"Cognitive-Behavioral Therapy","Web-Based Intervention","Mental Health","2026-06-26",{"date":466,"type":46},{"date":494,"type":22},"2026-09-01",{"date":496,"type":22},"2027-02-01",{"name":498,"class":86},"University of Coimbra",{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":63,"sex":18,"minAge":153,"maxAge":20,"enrollmentInfo":507,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":509,"conditions":510,"keywords":516,"overallStatus":242,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":54},"100645235","crest-samphire-guided-care-program-on-wellbeing-work-productivity-and-quality-of-life-100645235","NCT07679074","CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life","A 12-Week Prospective Cohort Study Evaluating the Efficacy of the Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life in Individuals With Menstrual and Pelvic Health Conditions","CREST","Inclusion Criteria:\n\n* Self-identified female, aged 18-65 years at the time of enrollment\n* Basic English literacy\n* Able and willing to provide informed consent electronically\n* Residing in the United States\n* Reporting mood or cognitive symptoms associated with menstruation, perimenopause, or menopause (must endorse a minimum of three of the following: irritability, emotional dysregulation, brain fog, fatigue, reduced concentration, sleep disruption, or low mood)\n* Symptoms present for at least 3 months and sufficiently severe to interfere with daily functioning, work performance, quality of life, or interpersonal relationships\n* Currently in full-time employment with medical benefits as part of compensation package\n* Access to a smartphone with internet access compatible with the Samphire mobile application\n* Able to safely operate the study device in the home environment\n* Willing to complete baseline, mid-program, and end-of-program questionnaires and engage with the 12-week guided care program\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding, or actively planning pregnancy during the study period\n* History of epilepsy or seizure disorder\n* Severe or unstable neurological disease that, in the opinion of the study team, may increase risk or interfere with participation\n* Implanted electronic or metal devices in the head, neck, or brain region contraindicated for tDCS use\n* Active scalp lesions, open wounds, or dermatologic conditions at electrode sites that may interfere with safe device use\n* Current diagnosis of schizophrenia, bipolar disorder, or other severe psychiatric condition that would make participation inappropriate, as determined by screening\n* Active suicidal ideation, recent suicidal behavior, or clinically significant self-injurious behavior, as determined by participant self-report during screening\n* Inability to provide informed consent or safely use the device in the home environment\n* Current participation in another interventional neurotechnology or drug study",{"count":508,"type":22},50,"This study evaluates the feasibility and efficacy of the Samphire Guided Care (SGC) program\n\n* a 12-week structured digital health program combining clinician-led onboarding, at-home neuromodulation using the Lutea tDCS device, neuromodulation coach support, and app-based symptom tracking - on work productivity, employee wellbeing, and quality of life in individuals experiencing mood and cognitive symptoms associated with menstruation, perimenopause, or menopause.",[511,512,513,514,32,28,515],"Premenstrual Syndrome","Premenstrual Dysphoric Disorder","Dysmenorrhea","Endometriosis","Pelvic Pain",[517,518,519,520,521,76,522,523,524,525,526,527,528,529,530],"tDCS","neuromodulation","hormonal health","menstrual symptoms","perimenopause","PMDD","PMS","work productivity","brain fog","mood","cognitive function","digital health","decentralized clinical trial","guided care","2026-06-25",{"date":273,"type":46},{"date":534,"type":46},"2026-06-01",{"date":536,"type":22},"2027-03-01",{"name":538,"class":539},"Samphire Group, Inc.","INDUSTRY",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":63,"sex":18,"minAge":353,"maxAge":20,"enrollmentInfo":547,"targetDuration":4,"studyType":23,"phases":548,"briefSummary":549,"conditions":550,"keywords":551,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":557,"startDateStruct":558,"completionDateStruct":559,"leadSponsor":560,"locationsCount":54},"100645147","effect-of-zenrest-lotus-seed--rice-germ-extract-blend-on-sleep-quality-in-menopausal-women-100645147","NCT07678359","Effect of ZenRest™ Lotus Seed & Rice Germ Extract Blend on Sleep Quality in Menopausal Women","A Randomized, Double-Blind, Placebo-Controlled, 6-Week Pilot Study to Evaluate the Effect of ZenRest™ Lotus Seed & Rice Germ Extract Blend on Sleep Quality in Menopausal Women","Inclusion Criteria:\n\n* Female, aged 40-65 years at time of enrollment\n* Confirmed menopausal status: (a) natural menopause (≥12 consecutive months of amenorrhea without other clinical cause), or (b) surgical menopause (bilateral oophorectomy with documented date of procedure)\n* Positive onboarding sleep screener: rates sleep quality as \"Fairly Bad\" or \"Very Bad\" AND reports sleep difficulty at least once per week in the prior month\n* PSQI global score \\>5 at T0 baseline assessment (formal eligibility gate)\n* Owns and actively uses an Oura Ring Generation 4 at time of enrollment\n* Demonstrates ≥80% Oura Ring wear compliance in the 30 days prior to enrollment, confirmed via Alethios platform sync at onboarding\n* Willing to wear Oura Ring Generation 4 continuously for 42 nights throughout the study period\n* Willing to maintain stable diet, sleep habits, medications, and supplement use throughout the 42-day study period\n* No planned major disruptions to sleep schedule, shift work, or travel across ≥3 time zones during the study period\n* Access to a smartphone or computer to complete eConsent and digital questionnaires\n* Able to provide informed consent via the Alethios eConsent platform\n\nExclusion Criteria:\n\n* Current use of prescription sleep medications (benzodiazepines, non-benzodiazepine hypnotics, doxepin, suvorexant) within 30 days of enrollment\n* Current use of melatonin supplements at doses \\>1 mg\u002Fday within 14 days of enrollment\n* Diagnosis of a clinically significant sleep disorder requiring treatment (obstructive sleep apnea unless adequately treated and stable, restless legs syndrome, narcolepsy)\n* Diagnosis of a major psychiatric disorder currently requiring pharmacological treatment\n* Current use of hormone replacement therapy initiated within 90 days of enrollment, or any planned changes to HRT during the study (stable long-term HRT is acceptable)\n* Regular use of GABAergic, serotonergic, or sedating supplements (valerian, passionflower, ashwagandha, kava) within 14 days of enrollment\n* Shift work or schedule regularly requiring sleep between 06:00 and 22:00\n* Planned travel across 3 or more time zones during the 42-day study period\n* Known allergy to lotus, rice, or related botanicals\n* Active cardiovascular, hepatic, renal, or neurological condition that in the PI's judgment would affect sleep or participant safety\n* Participation in another interventional study within 30 days of enrollment\n* In the opinion of the PI, any condition compromising participant safety or data integrity",{"count":156,"type":22},[25],"The goal of this clinical trial is to learn if ZenRest™ (Lotus Seed \\& Rice Germ Extract Blend) can help improve sleep quality in menopausal women aged 40-65 with mild-to-moderate sleep complaints.\n\nThe main questions it aims to answer are:\n\n* Does taking ZenRest™ daily improve subjective, participant-reported sleep quality compared to a placebo?\n* Does ZenRest™ improve objective sleep metrics, specifically sleep efficiency, when monitored via an Oura Ring wearable device?\n* Does the extract improve secondary sleep and lifestyle factors, such as insomnia severity, daytime sleepiness, and vitality? Researchers will compare ZenRest™ to a placebo (a look-alike capsule that contains no active ingredients) to see if the botanical blend has a measurable effect on sleep quality.",[35,28],[552,553,554,555,556,28,35],"ZenRest","Lotus Seed Extract","Rice Germ Extract","Spermidine","Neferine",{"date":273,"type":46},{"date":166,"type":22},{"date":50,"type":22},{"name":561,"class":539},"Nutraland USA, Inc.",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":283,"enrollmentInfo":570,"targetDuration":4,"studyType":23,"phases":572,"briefSummary":573,"conditions":574,"keywords":577,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":54},"100641340","effect-of-mandala-coloring-on-menopausal-attitude-perceived-stress-and-mindfulness-100641340","NCT07657429","Effect of Mandala Coloring on Menopausal Attitude, Perceived Stress and Mindfulness","The Effect of Mandala Coloring on Menopausal Attitudes, Perceived Stress, and Mindfulness in Women During Menopause: A Randomized Controlled Trial","MANDALA-MENO","* Inclusion Criteria:\n\n  * Women aged 45-55 years\n  * Being in the menopausal period (absence of menstruation for at least 12 months)\n  * Ability to read and understand Turkish\n  * Voluntary agreement to participate in the study\n* Exclusion Criteria:\n\n  * Diagnosed psychiatric or cognitive disorders\n  * Communication problems preventing participation\n  * Visual impairment or fine motor limitations preventing mandala coloring\n  * Use of hormone replacement therapy\n  * Regular participation in mandala coloring, mindfulness, or similar mind-body practices",{"count":571,"type":22},140,[25],"Menopause is a natural life stage associated with hormonal changes that may affect women physically and psychologically. During this period, women may experience increased stress levels, negative attitudes toward menopause, and decreased mindfulness. Mandala coloring is a structured art-based intervention that may promote relaxation and improve psychological well-being. This randomized controlled trial aims to evaluate the effect of mandala coloring on attitudes toward menopause, perceived stress, and mindfulness levels among menopausal women.",[28,575,576],"Psychological Stress","Mindfulness",[578,28,267,576,579,265],"Mandala Coloring","Women Health","2026-06-24",{"date":582,"type":46},"2026-06-29",{"date":584,"type":22},"2026-05-30",{"date":586,"type":22},"2026-09-30",{"name":588,"class":86},"Ondokuz Mayıs University",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":63,"sex":18,"minAge":596,"maxAge":597,"enrollmentInfo":598,"targetDuration":4,"studyType":23,"phases":600,"briefSummary":601,"conditions":602,"keywords":603,"overallStatus":242,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":611,"locationsCount":54},"100577459","phase-4-role-of-menopause-in-thermoregulation-100577459","NCT06798571","Role of Menopause in Thermoregulation","The Influence of Estrogen on the Thermoregulatory Responses to Heat Stress in Pre and Postmenopausal Women","Inclusion Criteria:\n\n* Women ages 42-64\n\nExclusion Criteria:\n\n* Chron's disease, diverticulitis, or similar gastrointestinal disease\n* Abnormal resting exercise electrocardiogram (ECG)\n* Tobacco use\n* High-risk determined by the Atherosclerotic Cardiovascular Disease (CVD) Risk Factor\n* Assessment\n* Using hormone therapy\n* Using hormonal contraceptives","42 Years","64 Years",{"count":599,"type":22},24,[182],"The frequency and severity of heat waves has increased in the last decades. Older adults (over 65 years) have impaired responses to heat stress making them at increased risk for adverse events. Previous heat waves report that women over 65 experience worse health outcomes than any other age group and age matched men.\n\nAging and reproductive hormones, specifically estrogen, independently alter responses to heat stress. However, the combined effects of low estrogen following menopause and aging on the response to heat stress are unknown. In this study, the investigators will identify the role of estrogen in pre and post menopausal women on thermoregulatory responses to heat stress.",[28,161],[604,605],"Thermoregulation","Heat Stress","2026-06-23",{"date":580,"type":46},{"date":609,"type":46},"2025-03-01",{"date":494,"type":22},{"name":612,"class":86},"Penn State University",{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":18,"minAge":353,"maxAge":379,"enrollmentInfo":620,"targetDuration":4,"studyType":23,"phases":621,"briefSummary":622,"conditions":623,"keywords":624,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":631,"completionDateStruct":632,"leadSponsor":634,"locationsCount":54},"100639154","evaluation-of-the-effects-of-lifestyle-medicine-and-mindfulness-based-group-medical-visits-on-stress-microbiome-and-quality-of-life-in-women-experiencing-perimenopause-and-menopause-100639154","NCT07619352","Evaluation of the Effects of Lifestyle Medicine and Mindfulness-based Group Medical Visits on Stress, Microbiome, and Quality of Life in Women Experiencing Perimenopause and Menopause","A Pilot Study to Evaluate the Effects of Lifestyle Medicine and Mindfulness-based Group Medical Visits on Stress, Microbiome, and Quality of Life in Women Experiencing Perimenopause and Menopause","Inclusion Criteria:\n\n1. Biological female.\n2. Age 40 to 60.\n3. Irregular menstruation for 3 months and experiencing perimenopause or menopause as determined by reporting at least one symptom on the Menopause Quality of Life Questionnaire (MENQOL).\n4. Ability to attend group medical visits monthly, in-person for 8 months, at The Ohio State University Center for Integrative Health as well as the baseline and end of study visit.\n5. Ability to participate in the Mindfulness in Motion (MIM) study activities.\n6. Ability and willingness to download MyCap, the smartphone app that securely links participant study responses to the REDCap study project.\n7. WiFi connectivity or LTE to allow use of MyCap when not at OSU study site\n\nExclusion Criteria:\n\n1. Participants with surgically induced menopause, e.g., hysterectomy, oophorectomy.\n2. Currently receiving or planning to receive hormone therapy for perimenopausal or menopausal symptoms.\n3. Currently taking or planning to take hormonal contraceptives.\n4. Currently taking or planning to take hormone altering medications; i.e. Taxol.\n5. Currently taking probiotics, Siberian rhubarb (Rheum rhaponticum), Black cohosh (Actaea racemosa), Chaste tree berry (Vitex agnus-castus).\n6. Inability to read and\u002For understand English (consent and questionnaires in English).\n7. Current severe alcohol or substance abuse disorder.\n8. Participants with documented cognitive disorder that limits the ability to independently read, understand, and\u002For complete the survey or biological; i.e. dementia, Alzheimer's or biological tests.\n9. Participants with major psychiatric disorders not controlled by medication or other psychiatric treatments.",{"count":97,"type":22},[25],"While perimenopause and menopause are natural biological transitions, women may experience a wide range of physical, emotional, and cognitive symptoms. Although pharmacological options for symptom relief are available, these options may not be acceptable or suitable for all women. Integrative approaches for symptom relief, offered through group medical visits, may complement traditional therapies by increasing access to providers, allowing more time for focused education, and fostering supportive discussions with other women experiencing similar symptoms of perimenopause or menopause.\n\nThe purpose of this study is to assess the effectiveness of eight monthly group medical visits that incorporate individual physical assessments, focused education on the foundational elements of Lifestyle Medicine relative to health and well-being, mindfulness practices, and community-building discussions with women experiencing perimenopause or menopause. Individual outcomes, obtained before the group medical visits begin, at each monthly group medical visit, and four months after the group medical visits are completed, will include measures of participants' perimenopause or menopause symptoms, stress, inflammation, microbiome (good bacteria in the body), height\u002Fweight, body mass index (BMI), systolic and diastolic blood pressure, and self-reported perceptions of physical, mental, and social health.\n\nEach 120-minute monthly group medical visit, led by a specially trained nurse practitioner and a mindfulness instructor, will include a brief physical assessment, educational discussions related to menopause and lifestyle medicine, experiential mindfulness practices, and the development of individual health and well-being goals.",[32,28],[521,76,625,626,627,628],"stress","microbiome","quality of life","women","2026-06-18",{"date":606,"type":46},{"date":81,"type":22},{"date":633,"type":22},"2028-08-30",{"name":635,"class":86},"Ohio State University",{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":4,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":283,"enrollmentInfo":643,"targetDuration":4,"studyType":23,"phases":645,"briefSummary":646,"conditions":647,"keywords":650,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":659,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":665,"locationsCount":54},"100641801","meleis-transition-theory-based-education-and-counseling-program-in-menopausal-women-100641801","NCT07657078","Meleis' Transition Theory-Based Education and Counseling Program in Menopausal Women","The Effect of a Meleis' Transition Theory-Based Education and Counseling Program on Menopausal Symptoms, Perimenopausal Depression, and Menopause-Specific Quality of Life in Menopausal Women: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Female participants aged 45 to 55 years\n* Naturally menopausal women\n* Menopause duration not exceeding 2 years\n* Experiencing menopausal symptoms\n* Sexually active\n* Able to read and write Turkish\n* Willing to participate voluntarily\n* Able to provide written informed consent\n* Not currently receiving hormone replacement therapy\n* No history of psychiatric disorders\n* No previous menopause-related education\n\nExclusion Criteria:\n\n* Failure to continue participation in the study\n* Failure to attend education and counseling sessions\n* Withdrawal from the study at any time\n* Withdrawal of informed consent\n* Loss to follow-up",{"count":644,"type":22},114,[25],"This randomized controlled trial aims to evaluate the effectiveness of a Meleis' Transition Theory-based education and counseling program on menopausal symptoms, perimenopausal depression, and menopause-specific quality of life among naturally menopausal women aged 45 to 55 years.\n\nParticipants will be randomly assigned to either the intervention group or the control group. The intervention group will receive a structured four-week education and counseling program based on Meleis' Transition Theory, supported by a secure online messaging group and follow-up counseling sessions. The control group will receive routine care and standard information during the study period and will be offered a one-day educational session after completion of the final assessment.\n\nThe outcomes will be measured at baseline and Week 16 using the Menopause Rating Scale, the Perimenopausal Depression Scale, and the Menopause-Specific Quality of Life Questionnaire-II.",[28,648,649],"Menopausal Symptoms","Perimenopausal Depression",[28,360,651,652,653,138,654,655,656,657],"Meleis' Transition Theory","Education","Counseling","Perimenopausal depression","Quality of life","Women's health","Nursing","2026-06-17",{"date":660,"type":46},"2026-06-22",{"date":662,"type":22},"2026-06-15",{"date":664,"type":22},"2026-10-15",{"name":666,"class":86},"Ankara Medipol University",{"id":668,"slug":669,"hasResults":12,"nctId":670,"briefTitle":671,"officialTitle":672,"acronym":4,"eligibilityCriteria":673,"healthyVolunteers":63,"sex":18,"minAge":353,"maxAge":674,"enrollmentInfo":675,"targetDuration":4,"studyType":23,"phases":677,"briefSummary":678,"conditions":679,"keywords":685,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":662,"lastUpdatePostDateStruct":688,"startDateStruct":689,"completionDateStruct":690,"leadSponsor":692,"locationsCount":4},"100641575","veda-study-dhea-vs-estradiol-100641575","NCT07574216","VEDA Study (DHEA vs Estradiol)","The Use of Vaginal Estrogen vs DHEA in Perimenopausal and Menopausal Women","Inclusion Criteria:\n\n* Peri- or post-menopausal status\n* Presence of any genitourinary or vaginal symptom (e.g., dryness, itching, discomfort, dyspareunia)\n* Willingness and ability to use vaginal therapy\n* Ability to provide informed consent\n* English speaker\n* Ages 40-90\n\nExclusion Criteria:\n\n* Use of systemic hormone therapy within the last 6 months\n* Gynecologic malignancy\n* Known allergy to study medications\n* Active vaginal infection at enrollment\n* Prior pelvic radiation","90 Years",{"count":676,"type":22},324,[25],"This study is being done to compare two vaginal treatments, vaginal estrogen and vaginal DHEA, that are used to treat vaginal and urinary symptoms related to menopause. These symptoms may include vaginal dryness, discomfort, painful intercourse, or urinary problems and can affect quality of life and sexual health. Women who choose to participate will be randomly assigned to use one of the two treatments for a set period of time. Participants will complete questionnaires about their symptoms and sexual health and have simple vaginal testing at the beginning and end of the study. The goal of this research is to better understand how these treatments affect vaginal health and sexual function so healthcare providers can make informed treatment decisions and improve care for postmenopausal women.",[680,681,682,28,683,684],"Post-menopause","Pre-menopause","Sexual Function","Vaginal Dryness","Painful Intercourse",[686,687],"DHEA","vaginal estrogen",{"date":658,"type":46},{"date":534,"type":22},{"date":691,"type":22},"2031-12-31",{"name":693,"class":86},"University of Arizona"]